Jorunnamycin A Suppresses Stem-Like Phenotypes and Sensitizes Cisplatin-Induced Apoptosis in Cancer Stem-Like Cell-Enriched Spheroids of Human Lung Cancer Cells.
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
Down-Regulation
/ drug effects
Drug Synergism
Humans
Isoquinolines
/ chemistry
Lung Neoplasms
/ drug therapy
Nanog Homeobox Protein
/ genetics
Neoplastic Stem Cells
/ drug effects
Octamer Transcription Factor-3
/ genetics
Proto-Oncogene Proteins c-bcl-2
/ metabolism
Quinolones
/ chemistry
SOXB1 Transcription Factors
/ genetics
Spheroids, Cellular
/ drug effects
Transcription Factors
/ genetics
Tumor Suppressor Protein p53
/ metabolism
Xestospongia
/ chemistry
cancer stem-like cells
cisplatin
jorunnamycin A
lung cancer
stemness transcription factors
β-catenin
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
04
04
2021
revised:
29
04
2021
accepted:
30
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
17
11
2021
Statut:
epublish
Résumé
It has been recognized that cancer stem-like cells (CSCs) in tumor tissue crucially contribute to therapeutic failure, resulting in a high mortality rate in lung cancer patients. Due to their stem-like features of self-renewal and tumor formation, CSCs can lead to drug resistance and tumor recurrence. Herein, the suppressive effect of jorunnamycin A, a bistetrahydroisoquinolinequinone isolated from Thai blue sponge
Identifiants
pubmed: 34063628
pii: md19050261
doi: 10.3390/md19050261
pmc: PMC8147647
pii:
doi:
Substances chimiques
BCL2 protein, human
0
Isoquinolines
0
NANOG protein, human
0
Nanog Homeobox Protein
0
Octamer Transcription Factor-3
0
POU5F1 protein, human
0
Proto-Oncogene Proteins c-bcl-2
0
Quinolones
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
TP53 protein, human
0
Transcription Factors
0
Tumor Suppressor Protein p53
0
jorunnamycin A
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Chulalongkorn University
ID : 90th Anniversary of Chulalongkorn University
Organisme : Chulalongkorn University
ID : Ratchadaphiseksomphot Endowment Fund (grant no. CU_GR_62_20_33_01)
Organisme : National Research Council of Thailand (NRCT)
ID : Mid-Career Research Grant (RSA 6280009)
Références
Oncol Rep. 2014 Dec;32(6):2437-44
pubmed: 25230779
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Int J Oncol. 2017 Apr;50(4):1341-1351
pubmed: 28259926
Oncogene. 2019 May;38(22):4412-4424
pubmed: 30742096
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575023
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Sci Rep. 2020 Jun 1;10(1):8875
pubmed: 32483269
Front Oncol. 2017 May 05;7:80
pubmed: 28529925
PLoS Biol. 2009 Jun 2;7(6):e1000121
pubmed: 19492080
Mol Med Rep. 2015 Jun;11(6):4165-73
pubmed: 25625235
Oncogene. 2019 Jul;38(27):5440-5456
pubmed: 30936460
Ther Adv Med Oncol. 2020 May 18;12:1758835920923430
pubmed: 32489432
Clin Transl Med. 2013 Jan 17;2(1):3
pubmed: 23369605
Oncol Lett. 2018 May;15(5):6791-6798
pubmed: 29731860
Oncogene. 2008 Nov 6;27(52):6646-56
pubmed: 18663354
Mar Drugs. 2019 Feb 11;17(2):
pubmed: 30754694
Oncol Lett. 2018 Oct;16(4):4821-4828
pubmed: 30250547
Clin Cancer Res. 2008 Dec 15;14(24):8205-12
pubmed: 19088037
Sci Rep. 2017 Jul 17;7(1):5593
pubmed: 28717179
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6
pubmed: 19805294
Cancer Res. 2014 Mar 1;74(5):1554-65
pubmed: 24436149
Cancer Res. 2007 May 15;67(10):4827-33
pubmed: 17510412
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1180-8
pubmed: 23024022
J Nat Prod. 2003 Nov;66(11):1441-6
pubmed: 14640515
Front Med (Lausanne). 2020 Mar 24;7:90
pubmed: 32266275
Cancer Lett. 2016 May 1;374(2):292-303
pubmed: 26940070
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Mar Drugs. 2020 Aug 10;18(8):
pubmed: 32785022
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
J Cell Mol Med. 2019 Dec;23(12):8184-8195
pubmed: 31638335
J Nat Prod. 2003 Apr;66(4):544-7
pubmed: 12713412
Cell Death Differ. 2006 Aug;13(8):1256-9
pubmed: 16710363
J Vis Exp. 2011 Apr 24;(50):
pubmed: 21540825
Cell Biol Int. 2012 Mar 1;36(3):261-5
pubmed: 22397496
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Sci Rep. 2017 Apr 06;7:46246
pubmed: 28383051
Oncotarget. 2017 Aug 3;8(42):72544-72563
pubmed: 29069808
Int J Mol Sci. 2015 Nov 13;16(11):27288-301
pubmed: 26580604
J Nat Prod. 2017 May 26;80(5):1541-1547
pubmed: 28459574
PLoS One. 2020 Jan 3;15(1):e0227174
pubmed: 31900469
Adv Exp Med Biol. 2016;890:57-74
pubmed: 26703799
Int J Oncol. 2020 May;56(5):1083-1092
pubmed: 32319573
Transl Lung Cancer Res. 2013 Jun;2(3):172-9
pubmed: 25806230
Cell Oncol (Dordr). 2017 Oct;40(5):497-510
pubmed: 28677037
PLoS One. 2014 Jun 18;9(6):e100168
pubmed: 24940615
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366089
PLoS One. 2020 Mar 26;15(3):e0230230
pubmed: 32214328
Cancers (Basel). 2018 Feb 16;10(2):
pubmed: 29462906
Ann Oncol. 2011 Nov;22(11):2466-2470
pubmed: 21321089
Bio Protoc. 2015 Nov 20;5(22):1-11
pubmed: 29468185
Curr Top Dev Biol. 2014;107:207-233
pubmed: 24439808
Cell Death Dis. 2017 Apr 13;8(4):e2746
pubmed: 28406482
Front Immunol. 2018 Jun 19;9:1412
pubmed: 29971070
Stem Cells Int. 2017;2017:5619472
pubmed: 28473858
PLoS One. 2008 Jul 09;3(7):e2637
pubmed: 18612434
Cancer Res. 2015 Oct 1;75(19):4003-11
pubmed: 26292361
J Drug Target. 2019 Mar;27(3):257-269
pubmed: 29911902
Cell Res. 2012 Mar;22(3):457-72
pubmed: 22357481
Onco Targets Ther. 2018 Sep 25;11:6197-6207
pubmed: 30288055
Chem Rev. 2002 May;102(5):1669-730
pubmed: 11996547
Cancer Res. 2014 Mar 1;74(5):1566-75
pubmed: 24413534
Cancers (Basel). 2011 Mar 15;3(1):1351-71
pubmed: 24212665
Anticancer Agents Med Chem. 2013 May;13(4):576-80
pubmed: 22934707
Oncogenesis. 2015 Nov 30;4:e177
pubmed: 26619402
Mol Clin Oncol. 2014 Jan;2(1):111-115
pubmed: 24649317
J Nat Prod. 2016 Aug 26;79(8):2089-93
pubmed: 27487087
Lung Cancer Manag. 2014 Jan 1;3(1):67-75
pubmed: 25342981
Front Oncol. 2018 Aug 28;8:347
pubmed: 30211124
Stem Cell Rev Rep. 2016 Aug;12(4):492-9
pubmed: 27207017
Cell Death Dis. 2019 Sep 10;10(9):660
pubmed: 31506430
Mol Cell. 2012 Nov 30;48(4):627-40
pubmed: 23041284
J Nat Prod. 2019 Jul 26;82(7):1861-1873
pubmed: 31260310
Cancer Res. 2017 Jun 1;77(11):3082-3091
pubmed: 28416482
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Chem Pharm Bull (Tokyo). 2007 Jan;55(1):81-6
pubmed: 17202706
Tumour Biol. 2016 Jan;37(1):685-98
pubmed: 26242260
Cancer Biol Ther. 2016;17(1):1-10
pubmed: 26618281
Cancer Res. 2010 Dec 15;70(24):10433-44
pubmed: 21159654
Anticancer Res. 2017 Feb;37(2):615-621
pubmed: 28179308
PLoS One. 2013 May 01;8(5):e54659
pubmed: 23658677
Stem Cell Investig. 2018 Mar 14;5:6
pubmed: 29682513
Evid Based Complement Alternat Med. 2015;2015:836564
pubmed: 26339272
Cancer Res. 2013 Jan 1;73(1):406-16
pubmed: 23135908
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030